Review Transparency & Communication for New Molecular Entity NDAs & Original BLAs
Revision of a currently approved collection
No
Regular
08/31/2022
Requested
Previously Approved
36 Months From Approved
09/30/2022
240
140
210
211
0
0
This information collection supports Food and Drug Administration (FDA) performance goals and procedures as set forth under the Prescription Drug User Fee Act (PDUFA) and the Biosimilar User Fee Act (BsUFA). These goals are the result of agency, industry, and public input, as Congressionally mandated under the applicable statutes and represent the renewed performance goals agreed to by FDA in support of these respective programs.
US Code:
21 USC 301
Name of Law: Food, Drug, and Cosmetic Act
Since last OMB review and approval of the information collection, we have adjusted our burden estimate to include the same number of respondents for surveys and interviews, resulting in 100 additional responses, but one fewer hour, annually.
On behalf of this Federal agency, I certify that the collection of information encompassed by this request complies with 5 CFR 1320.9 and the related provisions of 5 CFR 1320.8(b)(3).
The following is a summary of the topics, regarding the proposed collection of information, that the certification covers:
(i) Why the information is being collected;
(ii) Use of information;
(iii) Burden estimate;
(iv) Nature of response (voluntary, required for a benefit, or mandatory);
(v) Nature and extent of confidentiality; and
(vi) Need to display currently valid OMB control number;
If you are unable to certify compliance with any of these provisions, identify the item by leaving the box unchecked and explain the reason in the Supporting Statement.